Developer docs
API playgroundTry for free, no card

Search company profiles

Iris Pharma

Full company profile

uuid000b9gz

Namestring
Iris Pharma
Legal namestring
Iris Pharma
Websiteurl
iris-pharma.com
Company typeenum
Private
Founded yearint
1989
Descriptiontext

Iris Pharma is a France-based, privately held contract research organization (CRO) founded in 1989 by Dr. Pierre-Paul Elena, specializing exclusively in ophthalmic drug and medical device development. The company operates from its headquarters and preclinical facility in La Gaude (registered office in Grasse), with additional R&D premises at the Institut de la Vision in Paris, and employs 51-100 staff. Its service portfolio spans three integrated pillars: early testing (efficacy and proof-of-concept studies, early pharmacokinetics, pilot toxicology, formulation and delivery), preclinical development (in vivo pharmacology using a library of validated ocular disease models, GLP-compliant ocular tolerance and safety testing, and GLP pharmacokinetics with analytical method validation), and full-service clinical trial operations (Phase I-IV clinical operations, medical writing, regulatory affairs, central laboratory, data management and statistics).

The company serves enterprise pharmaceutical and biotechnology clients globally, with 8 of the world's top 10 pharmaceutical companies cited as clients and nearly 70 ocular drugs and medical devices brought to market in partnership over its 30+ year history. Proprietary and licensed technical assets include the EYEPRIM device (exclusive license from OPIA Technologies for ocular surface biopsies), advanced imaging and biochemical quantification equipment (HRA-OCT Spectralis, Luminex Lx200), and ANSM GLP certification with Status 'A' for human medicines and conformity for medical devices (most recently renewed February 2024). Revenue is generated through B2B professional services contracts quoted on a project basis, acquired primarily through enterprise sales, scientific conference presence (ARVO, BIO, ESCRS, AAO, Eyecelerator), and direct business development with R&D and procurement teams. Distribution is direct enterprise sales with global geographic reach including EMEA, North America, and Asia Pacific.

Short descriptiontext

Iris Pharma is a France-based ophthalmology-focused contract research organization (CRO) founded in 1989, providing preclinical and clinical research services for ocular drugs and medical devices to global pharmaceutical and biotechnology clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLa Gaude, France
HQ citystring
La Gaude
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic CRO services, preclinical ophthalmology studies, clinical ophthalmic trials, ocular drug development, GLP ocular safety testing
Industry3 codes
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
NAICS code1 code
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Ophthalmic Contract Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Preclinical CRO Services
TypeProfessional Services
Description

Provides preclinical studies including in vivo pharmacology, GLP ocular tolerance/safety, GLP pharmacokinetics, and formulation/delivery services for ophthalmic drug and device development.

iris-pharma.com
2Clinical Trial Services
TypeProfessional Services
Description

Full-service clinical research operations including clinical operations, medical writing, regulatory affairs, central laboratory, data management and statistics for Phase I-IV ophthalmic clinical trials.

iris-pharma.com
3Consulting Services
TypeProfessional Services
Description

Strategic consulting to help clients determine best indication for molecules and products in development, and ophthalmic drug development program advisory services.

iris-pharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Iris Pharma is a contract research organization (CRO) exclusively dedicated to ophthalmology, providing preclinical and clinical research services for ocular drugs and medical devices. Its service portfolio spans early testing (efficacy, pharmacokinetics, tolerance, formulation), preclinical development (in vivo pharmacology, GLP ocular toxicology and pharmacokinetics), and clinical trials (Phase I-IV clinical operations, medical writing, regulatory affairs, central laboratory, data management) covering ocular surface to posterior segment indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Nearly 70 ocular drugs and medical devices brought to market in 30 years
+1 more record
Product overview1 text field

Iris Pharma is a leading contract research organization (CRO) dedicated to ophthalmic research, offering a comprehensive suite of services from the ocular surface to the posterior segment of the eye. The company's portfolio centers on three core service pillars: (1) Early Testing Services including efficacy & proof of concept, early pharmacokinetics, pilot tolerance & safety, and formulation & delivery; (2) Preclinical Development Services encompassing in vivo pharmacology studies with specialized animal models (angiogenesis, neurodegeneration, glaucoma, allergy, inflammation, dry eye, corneal wound healing, pain, and surgery models), GLP Ocular Tolerance & Safety testing, and GLP Ocular Pharmacokinetics with analytical method validation; and (3) Clinical Trial Services covering clinical operations, medical writing, regulatory affairs, central laboratory, and data management. The company also provides specialized capabilities through the EYEPRIM device (licensed from OPIA Technologies) for ocular surface biopsies, strategic consulting for drug development programs, and cellular/molecular biology assays. Iris Pharma's unique value proposition lies in its specialized ophthalmology focus and expert network, having partnered with clients to bring nearly 70 ocular drugs and medical devices to market since its founding in 1989.

Product and service11 records
1Preclinical Development Services
CategoryPreclinical CRO Services
Description

Comprehensive preclinical ophthalmology services for pharmaceutical and biotech clients, including in vivo pharmacology studies, GLP Ocular Tolerance & Safety testing, and GLP Ocular Pharmacokinetics, covering the full spectrum from early preclinical through regulatory submission.

2In vivo Pharmacology Studies
CategoryPreclinical CRO Services
Description

In vivo preclinical ocular models including angiogenesis & permeability, ocular neurodegeneration, ocular hypertension & glaucoma, ocular allergy, ocular inflammation, dry eye syndrome, corneal wound healing, ocular pain, and ocular surgery models.

3Early Testing Services
CategoryPreclinical CRO Services
Description

Early-stage testing services for ocular drug and device programs, including efficacy & proof of concept, early pharmacokinetics, pilot tolerance & safety testing, and formulation & delivery optimization.

4Clinical Trial Services
CategoryClinical CRO Services
Description

Full-service clinical research capabilities for ophthalmic trials, including clinical operations, medical writing, regulatory affairs, central laboratory, and data management & statistics across multiple ophthalmic indications and countries.

5EYEPRIM Device
CategorySpecialized Ophthalmic Device
Description

Patented medical device for performing conjunctival impressions to collect the most superficial layer of conjunctival epithelial cells (both goblet and non-goblet cells) from the conjunctival mucosa in a quasi-painless and non-invasive way for analyses and diagnosis.

6Ocular Disease Models
CategoryPreclinical CRO Services
Description

Specialized animal models for ocular diseases including age-related macular degeneration (dry and wet/exudative forms), diabetic retinopathy, retinitis pigmentosa, glaucoma, dry eye syndrome, uveitis, cataract, conjunctivitis, and ocular rosacea.

7GLP Toxicology & Safety Testing
CategoryPreclinical CRO Services
Description

GLP-compliant ocular tolerance and safety studies including acute local toxicity, chronic local toxicity, corneal anesthesia tests, ocular histopathology, lacrimation tests, and pupillary diameter assessments.

8GLP Ocular Pharmacokinetics
CategoryPreclinical CRO Services
Description

Pharmacokinetic and toxicokinetic studies with analytical method validation for ocular matrices using specialized techniques and equipment.

9Ophthalmic Drug Development Consulting
CategoryConsulting Services
Description

Strategic consulting services for ophthalmic drug development programs including regulatory requirements guidance, data assembly, key studies identification, and development roadmap planning.

10Cellular and Molecular Biology Assays
CategoryLaboratory / Assay Services
Description

Laboratory services for ocular biomarker analysis using cellular and molecular biology techniques to support preclinical and clinical research.

11Formulation & Delivery Services
CategoryPreclinical CRO Services
Description

Preclinical formulation development and drug delivery optimization services including bench formulation and drug delivery systems evaluation.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-02-01
Description

Strategic partnership to integrate quality of life assessment in clinical evaluation of new products for visually impaired. Combines Streetlab's expertise in mobility and quality of life for visually impaired with Iris Pharma's preclinical and clinical CRO services.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2011-04-21
Description

Long-term license agreement for EYEPRIM device development in animal studies. Iris Pharma obtained exclusive license for using EYEPRIM device to perform ocular surface biopsies in preclinical research activities. Device enables conjunctival impression cytology for quasi-painless, non-invasive cell collection.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic alliance for ophthalmic drug development services. Collaboration enhances preclinical and clinical research capabilities for mutual clients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic alliance to expand clinical research capabilities in ophthalmology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic alliance for clinical research operations in the USA, expanding Iris Pharma's geographic reach.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership and facilities at the Vision Institute in Paris. Iris Pharma opened new premises at the Institut de la Vision for enhanced R&D collaboration with leading vision researchers.

7Clirophtha
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Merger creating a unique ophthalmology CRO entity, combining capabilities and expertise of both organizations.

iris-pharma.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Mid-to-large global CRO with relevant ophthalmology trial capabilities. Increasingly competing for specialty clinical programs including ophthalmology with a full-service model.

TypeBroad incumbent
Description

Major global CRO offering ophthalmology clinical trial services among many other therapeutic areas. Relevant peer for larger Phase II/III ophthalmology programs where ICON's scale and global site network are competitive advantages.

TypeBroad incumbent
Description

Large preclinical and clinical CRO with ophthalmology capabilities as part of a broader portfolio. Competes with Iris Pharma on the preclinical/GLP side, leveraging significantly greater scale and global infrastructure.

TypeBroad incumbent
Description

Global full-service CRO with established ophthalmology practice. Competes with Iris Pharma for large multi-country ophthalmology trials where sponsors value global reach and integrated data/technology services.

TypeDirect peer
Description

US-headquartered ophthalmology-focused CRO offering preclinical and clinical research services for ocular therapies. Most directly comparable to Iris Pharma given its exclusive ophthalmology focus, full preclinical-to-clinical service mix, and similar sponsor base of large pharma and biotech.

TypeDirect peer
Description

Specialty ophthalmology CRO providing preclinical and clinical services for ocular drug development. Competes with Iris Pharma for the same ophthalmology sponsor programs and offers overlapping capabilities around ophthalmic clinical trial design and execution.

TypeBroad incumbent
Description

Global CRO/CDMO with preclinical and clinical ophthalmology services as part of broader discovery-through-trial offering. Comparable on preclinical animal studies and emerging as a competitor for ophthalmology sponsors.

8Clirophtha
TypeDirect peer
Description

Ophthalmology-specialized clinical CRO that merged with Iris Pharma in 2021 to form a combined entity. Direct comparable in therapeutic focus, customer profile, and service line; effectively now part of the Iris platform.

TypeBroad incumbent
Description

Diversified CRO and central laboratory services business with ophthalmology practice. Overlaps with Iris Pharma on central lab and clinical operations for ophthalmology trials, with substantially broader portfolio.

TypeEmerging player
Description

China-headquartered CRO with growing ophthalmology preclinical capabilities and US/EU footprint expansion. Represents an emerging competitor in the ophthalmology preclinical market, particularly attractive to sponsors seeking Asia-based development partners.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Iris Pharma

Ophthalmic Contract Research Servicesiris-pharma.com

Iris Pharma is a France-based ophthalmology-focused contract research organization (CRO) founded in 1989, providing preclinical and clinical research services for ocular drugs and medical devices to global pharmaceutical and biotechnology clients.

What Iris Pharma does

Iris Pharma is a France-based, privately held contract research organization (CRO) founded in 1989 by Dr. Pierre-Paul Elena, specializing exclusively in ophthalmic drug and medical device development. The company operates from its headquarters and preclinical facility in La Gaude (registered office in Grasse), with additional R&D premises at the Institut de la Vision in Paris, and employs 51-100 staff. Its service portfolio spans three integrated pillars: early testing (efficacy and proof-of-concept studies, early pharmacokinetics, pilot toxicology, formulation and delivery), preclinical development (in vivo pharmacology using a library of validated ocular disease models, GLP-compliant ocular tolerance and safety testing, and GLP pharmacokinetics with analytical method validation), and full-service clinical trial operations (Phase I-IV clinical operations, medical writing, regulatory affairs, central laboratory, data management and statistics).

The company serves enterprise pharmaceutical and biotechnology clients globally, with 8 of the world's top 10 pharmaceutical companies cited as clients and nearly 70 ocular drugs and medical devices brought to market in partnership over its 30+ year history. Proprietary and licensed technical assets include the EYEPRIM device (exclusive license from OPIA Technologies for ocular surface biopsies), advanced imaging and biochemical quantification equipment (HRA-OCT Spectralis, Luminex Lx200), and ANSM GLP certification with Status 'A' for human medicines and conformity for medical devices (most recently renewed February 2024). Revenue is generated through B2B professional services contracts quoted on a project basis, acquired primarily through enterprise sales, scientific conference presence (ARVO, BIO, ESCRS, AAO, Eyecelerator), and direct business development with R&D and procurement teams. Distribution is direct enterprise sales with global geographic reach including EMEA, North America, and Asia Pacific.

Iris Pharma firmographics

Firmographics
Name
Iris Pharma
Legal name
Iris Pharma
Website
https://iris-pharma.com
Company type
Private
Founded year
1989
Operating status
Operating
Headcount range
51–100 employees
Short description
Iris Pharma is a France-based ophthalmology-focused contract research organization (CRO) founded in 1989, providing preclinical and clinical research services for ocular drugs and medical devices to global pharmaceutical and biotechnology clients.
Ownership category
akta.pro rank

Iris Pharma industry classification

Industry
Product category
Ophthalmic Contract Research Services
NAICS
Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs

Keywords

  • Ophthalmic CRO services
  • Preclinical ophthalmology studies
  • Clinical ophthalmic trials
  • Ocular drug development
  • GLP ocular safety testing

Where Iris Pharma is headquartered

Location

Headquarters

HQ city
La Gaude
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Iris Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Preclinical CRO Services: Provides preclinical studies including in vivo pharmacology, GLP ocular tolerance/safety, GLP pharmacokinetics, and formulation/delivery services for ophthalmic drug and device development.
  2. Clinical Trial Services: Full-service clinical research operations including clinical operations, medical writing, regulatory affairs, central laboratory, data management and statistics for Phase I-IV ophthalmic clinical trials.
  3. Consulting Services: Strategic consulting to help clients determine best indication for molecules and products in development, and ophthalmic drug development program advisory services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Iris Pharma product offering

Product offering

Core offering

Iris Pharma is a contract research organization (CRO) exclusively dedicated to ophthalmology, providing preclinical and clinical research services for ocular drugs and medical devices. Its service portfolio spans early testing (efficacy, pharmacokinetics, tolerance, formulation), preclinical development (in vivo pharmacology, GLP ocular toxicology and pharmacokinetics), and clinical trials (Phase I-IV clinical operations, medical writing, regulatory affairs, central laboratory, data management) covering ocular surface to posterior segment indications.

Product overview

Iris Pharma is a leading contract research organization (CRO) dedicated to ophthalmic research, offering a comprehensive suite of services from the ocular surface to the posterior segment of the eye. The company's portfolio centers on three core service pillars: (1) Early Testing Services including efficacy & proof of concept, early pharmacokinetics, pilot tolerance & safety, and formulation & delivery; (2) Preclinical Development Services encompassing in vivo pharmacology studies with specialized animal models (angiogenesis, neurodegeneration, glaucoma, allergy, inflammation, dry eye, corneal wound healing, pain, and surgery models), GLP Ocular Tolerance & Safety testing, and GLP Ocular Pharmacokinetics with analytical method validation; and (3) Clinical Trial Services covering clinical operations, medical writing, regulatory affairs, central laboratory, and data management. The company also provides specialized capabilities through the EYEPRIM device (licensed from OPIA Technologies) for ocular surface biopsies, strategic consulting for drug development programs, and cellular/molecular biology assays. Iris Pharma's unique value proposition lies in its specialized ophthalmology focus and expert network, having partnered with clients to bring nearly 70 ocular drugs and medical devices to market since its founding in 1989.

Differentiator

Problem solved

Functional benefit

Products and services

  • Preclinical Development Services Comprehensive preclinical ophthalmology services for pharmaceutical and biotech clients, including in vivo pharmacology studies, GLP Ocular Tolerance & Safety testing, and GLP Ocular Pharmacokinetics, covering the full spectrum from early preclinical through regulatory submission.
  • In vivo Pharmacology Studies In vivo preclinical ocular models including angiogenesis & permeability, ocular neurodegeneration, ocular hypertension & glaucoma, ocular allergy, ocular inflammation, dry eye syndrome, corneal wound healing, ocular pain, and ocular surgery models.
  • Early Testing Services Early-stage testing services for ocular drug and device programs, including efficacy & proof of concept, early pharmacokinetics, pilot tolerance & safety testing, and formulation & delivery optimization.
  • Clinical Trial Services Full-service clinical research capabilities for ophthalmic trials, including clinical operations, medical writing, regulatory affairs, central laboratory, and data management & statistics across multiple ophthalmic indications and countries.
  • EYEPRIM Device Patented medical device for performing conjunctival impressions to collect the most superficial layer of conjunctival epithelial cells (both goblet and non-goblet cells) from the conjunctival mucosa in a quasi-painless and non-invasive way for analyses and diagnosis.
  • Ocular Disease Models Specialized animal models for ocular diseases including age-related macular degeneration (dry and wet/exudative forms), diabetic retinopathy, retinitis pigmentosa, glaucoma, dry eye syndrome, uveitis, cataract, conjunctivitis, and ocular rosacea.
  • GLP Toxicology & Safety Testing GLP-compliant ocular tolerance and safety studies including acute local toxicity, chronic local toxicity, corneal anesthesia tests, ocular histopathology, lacrimation tests, and pupillary diameter assessments.
  • GLP Ocular Pharmacokinetics Pharmacokinetic and toxicokinetic studies with analytical method validation for ocular matrices using specialized techniques and equipment.
  • Ophthalmic Drug Development Consulting Strategic consulting services for ophthalmic drug development programs including regulatory requirements guidance, data assembly, key studies identification, and development roadmap planning.
  • Cellular and Molecular Biology Assays Laboratory services for ocular biomarker analysis using cellular and molecular biology techniques to support preclinical and clinical research.
  • Formulation & Delivery Services Preclinical formulation development and drug delivery optimization services including bench formulation and drug delivery systems evaluation.

Quantifiable outcome

  • Nearly 70 ocular drugs and medical devices brought to market in 30 years
  • +1 more outcomes

Companies that use Iris Pharma

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Iris Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Iris Pharma partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor and core.

  • StreetlabminorStrategic or Co-development Partner · 1 February 2017Strategic partnership to integrate quality of life assessment in clinical evaluation of new products for visually impaired. Combines Streetlab's expertise in mobility and quality of life for visually impaired with Iris Pharma's preclinical and clinical CRO services.
  • OPIA TechnologiescoreOEM/ Whitelabel/ Licensing Partner · 21 April 2011Long-term license agreement for EYEPRIM device development in animal studies. Iris Pharma obtained exclusive license for using EYEPRIM device to perform ocular surface biopsies in preclinical research activities. Device enables conjunctival impression cytology for quasi-painless, non-invasive cell collection.
  • RxGencoreStrategic or Co-development PartnerStrategic alliance for ophthalmic drug development services. Collaboration enhances preclinical and clinical research capabilities for mutual clients.
  • PMI (Pharmaceutical Management Institute)coreStrategic or Co-development PartnerStrategic alliance to expand clinical research capabilities in ophthalmology.
  • OculoscoreStrategic or Co-development PartnerStrategic alliance for clinical research operations in the USA, expanding Iris Pharma's geographic reach.
  • Institut de la VisioncoreStrategic or Co-development PartnerResearch partnership and facilities at the Vision Institute in Paris. Iris Pharma opened new premises at the Institut de la Vision for enhanced R&D collaboration with leading vision researchers.
  • ClirophthacoreStrategic or Co-development PartnerMerger creating a unique ophthalmology CRO entity, combining capabilities and expertise of both organizations.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Iris Pharma competitors and assessment

Company assessment

Broad incumbents

  • Medpace Holdings: Mid-to-large global CRO with relevant ophthalmology trial capabilities. Increasingly competing for specialty clinical programs including ophthalmology with a full-service model.
  • ICON plc: Major global CRO offering ophthalmology clinical trial services among many other therapeutic areas. Relevant peer for larger Phase II/III ophthalmology programs where ICON's scale and global site network are competitive advantages.
  • Charles River Laboratories: Large preclinical and clinical CRO with ophthalmology capabilities as part of a broader portfolio. Competes with Iris Pharma on the preclinical/GLP side, leveraging significantly greater scale and global infrastructure.
  • IQVIA: Global full-service CRO with established ophthalmology practice. Competes with Iris Pharma for large multi-country ophthalmology trials where sponsors value global reach and integrated data/technology services.
  • WuXi AppTec: Global CRO/CDMO with preclinical and clinical ophthalmology services as part of broader discovery-through-trial offering. Comparable on preclinical animal studies and emerging as a competitor for ophthalmology sponsors.
  • LabCorp (Covance Clinical Services): Diversified CRO and central laboratory services business with ophthalmology practice. Overlaps with Iris Pharma on central lab and clinical operations for ophthalmology trials, with substantially broader portfolio.

Direct peers

  • Ora, Inc. US-headquartered ophthalmology-focused CRO offering preclinical and clinical research services for ocular therapies. Most directly comparable to Iris Pharma given its exclusive ophthalmology focus, full preclinical-to-clinical service mix, and similar sponsor base of large pharma and biotech.
  • Lexitas Pharma Services: Specialty ophthalmology CRO providing preclinical and clinical services for ocular drug development. Competes with Iris Pharma for the same ophthalmology sponsor programs and offers overlapping capabilities around ophthalmic clinical trial design and execution.
  • Clirophtha: Ophthalmology-specialized clinical CRO that merged with Iris Pharma in 2021 to form a combined entity. Direct comparable in therapeutic focus, customer profile, and service line; effectively now part of the Iris platform.

Emerging players

  • Pharmaron: China-headquartered CRO with growing ophthalmology preclinical capabilities and US/EU footprint expansion. Represents an emerging competitor in the ophthalmology preclinical market, particularly attractive to sponsors seeking Asia-based development partners.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Iris Pharma social profiles

Digital presence

Iris Pharma compliance and trust

Trust signal

Compliance3 records

Iris Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Iris Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Iris Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Iris Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iris Pharma

What does Iris Pharma do?

Iris Pharma is a contract research organization (CRO) exclusively dedicated to ophthalmology, providing preclinical and clinical research services for ocular drugs and medical devices. Its service portfolio spans early testing (efficacy, pharmacokinetics, tolerance, formulation), preclinical development (in vivo pharmacology, GLP ocular toxicology and pharmacokinetics), and clinical trials (Phase I-IV clinical operations, medical writing, regulatory affairs, central laboratory, data management) covering ocular surface to posterior segment indications.

Is Iris Pharma a public or private company?

Iris Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Iris Pharma founded?

Iris Pharma was founded in 1989. It employs 51 to 100 people.

Where is Iris Pharma based?

Iris Pharma is headquartered in La Gaude, France, in the Europe region.

How does Iris Pharma make money?

Three revenue lines are on record. Preclinical CRO Services are the primary driver. The others are clinical Trial Services and consulting Services.

Who are Iris Pharma's main competitors?

Broad incumbents on record are Medpace Holdings, ICON plc, Charles River Laboratories, IQVIA, WuXi AppTec and LabCorp (Covance Clinical Services). Direct peers are Ora, Inc., Lexitas Pharma Services and Clirophtha. Pharmaron is listed as an emerging player.

Does Iris Pharma have an API?

No public API is recorded for Iris Pharma.

What industry is Iris Pharma in?

Iris Pharma's product category is Ophthalmic Contract Research Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals